

Award Number:
W81XWH-09-2-0175

TITLE:
Proposal for Development of EBM-CDSS (Evidence-based Clinical Decision Support System) to Aid
Diagnosis and Prognostication in Terminally Ill Patients.

PRINCIPAL INVESTIGATOR:
Benjamin Djulbegovic, MD, PhD

CONTRACTING ORGANIZATION:
University of South Florida
Tampa, FL 33620

REPORT DATE:
October, 2010

TYPE OF REPORT:
Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
1. REPORT DATE (DD-MM-YYYY) 01-10-2010		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 25 SEP 2009 - 24 SEP 2010
4. TITLE AND SUBTITLE Development of EBM-CDSS (Evidence-Based Clinical Decision Support System) to Aid Prognostication in Terminally Ill Patients.		5a. CONTRACT NUMBER		
		5b. GRANT NUMBER W81XWH-09-2-0175		
		5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Dr. Djulbegovic Benjamin		5d. PROJECT NUMBER		
		5e. TASK NUMBER		
		5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of South Florida Tampa, FL 33620		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSOR/MONITOR'S ACRONYM(S)		
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				
13. SUPPLEMENTARY NOTES				
14. ABSTRACT Goal of the project is to develop an Evidence-based Clinical Decision Support (CDSS-EBM) system and make it available at the point of care to improve prognostication of the life expectancy of terminally ill patients to improve referral of patients to hospice. We have completed the research and development (R&D) committee review process at the James A. Haley veteran's hospital. We have obtained the University of South Florida's (USF) and Tampa General Hospital (TGH) institutional review board (IRB) authorization. We are in the process of obtaining final approvals from the James A. Haley Veteran's hospital and USAMRMC Office of Research Protections (ORP) Human Research Protections Office (HRPO). So far our key research accomplishments are as follows; we • Developed case report for data extraction from Tampa Bay Lifepath Hospice Center's data. • Developed decision curves for the SUPPORT prognostication model. • Developed the first version of the Rough Set Theory prognostication model. • Created a novel methodology that combines Decision Curve Analysis and Regret theory to compare multiple decision strategies based on the decision maker's personal attitudes towards each strategy. • Developed a new method for elicitation of patient preferences • Developed a pilot, web-based version of the CDSS-EBM for hospice referral and chronic pain management module.				
15. SUBJECT TERMS CDSS, SUPPORT, DEALE, Terminally ill, Hospice, Prognostication				
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 37
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U		
				19b. TELEPHONE NUMBER (include area code)

Table of contents	
	Page number
Introduction	4
Work done so far	4
Key Research Accomplishments	5
Reportable Outcomes	6
Conclusion	6
References	7
Appendices	8

Introduction

The goal of this project is to develop an Evidence-based Clinical Decision Support System (CDSS-EBM) available at the point of care which will improve prognostication of life expectancy of terminally ill patients and facilitate the hospice referral process. In addition, the CDSS-EBM will be expanded with a pain management module to assist physicians managing terminally ill patients or patients with chronic pain.

Work done so far:

We have completed the research and development (R&D) committee review process at the James A. Haley veteran's hospital and have obtained the approval letter. We have obtained the University of South Florida's (USF) and Tampa General Hospital (TGH) institutional review board (IRB) authorization.

We have submitted the required paperwork to the James A. Haley Veteran's hospital to obtain the authorization from the security officer and the final approval to initiate the study at the James A. Haley Veteran's hospital. We have submitted the required documents including the research protocol and informed consent forms to the regulatory specialist with the Telemedicine and Advanced Technology Research Center (TATRC), to secure the approval from the USAMRMC Office of Research Protections (ORP) Human Research Protections Office (HRPO). ***It should be noted that all our work so far has been theoretical using publicly available data-set (SUPPORT) as we are still awaiting for the final approval to begin our study by Human Research Protection Office (HRPO), Office of Research Protections (ORP) U.S. Army Medical Research & Materiel Command (USAMRMC).*** Nevertheless, we believe we have been highly productive and able to accomplish a number of important tasks.

We have also completed the hiring of personnel for the first retrospective phase of this project.

Our progress regarding each of the tasks outlined in the Statement of Work is as follows:

Task 1: we have developed the case report form that will allow us to retrieve data from the Lifepath Hospice's charts. Data to be retrieved include all variables used in the SUPPORT [3] prognostication model.

Task 2: We have acquired the original, retrospective dataset used to develop the SUPPORT prognostication model. We utilized this dataset in multiple ways. First we used the entire dataset to compute the decision curves related to the SUPPORT model and the alternatives of referring all, or no patients to hospice. The decision curves are used in decision curve analysis (DCA) [4] where each alternative strategy is compared based on the decision maker's personal preferences as they are described by a threshold probability. We found that the SUPPORT prognostication model is the preferable decision strategy for a large range of threshold probabilities (8% to 91%).

In addition, we used a portion of the SUPPORT dataset (patients with lung cancer only) to estimate their life expectancy. For this task, we utilized the DEALE [5] prognostication model and the lung cancer evidence tables created by our group (see Task 4). Since the SUPPORT prognostication model is reporting probability of survival and not life expectancy, we have modified the SUPPORT outcomes in order to compare them with the results of the DEALE model. We have concluded that, regarding lung cancer, more investigation is needed to formally compare the two models. We hope that with capturing additional data from the retrospective phase this will be possible, once we get approval to begin data collection.

Finally, the third use of the SUPPORT dataset was to develop an initial version of a Rough Set Theory (RST) [6] prognostication model for life expectancy. This version of the RST model uses the majority of the variables included in the SUPPORT model and it has shown promising prediction results. Further investigation is required to determine the

impact of reducing the number of variables utilized or the addition of qualitative variables such as physicians' choices such as continuation of treatment or referral to hospice. This will be possible when prospective phase of the study is approved /commenced.

Along with the work outlined in Task 2, we have developed a novel methodology for comparison of decision strategies based on regret theory and decision curve analysis. Our method takes into consideration personal preferences of decision makers by quantifying the consequences of wrong decisions. In fact, we have developed a new method for elicitation of patients' preferences, which represent a significant achievement toward individualized evidence-based decision-making. A paper has been submitted to BMC Medical Informatics and Decision Making [1] (revisions stage) and a presentation is scheduled for the Society for Medical Decision Making Annual meeting [2]. (see Appendix for full report).

Task 3: We have developed a pilot web based version of the CDSS-EBM to compute life expectancy for terminally ill patients based on the DEALE and SUPPORT prognostication models. This CDSS-EBM will be utilized to suggest optimal strategies for particular simulated patients. This pilot CDSS-EBM will facilitate the hospice referral procedure in three steps. First, the probabilities of survival and death for a specific patient are computed based on the SUPPORT prognostication model. Then, based on interviews with either the patient, his/her family, or his/her physician the system elicits personal preferences regarding continuation of life-sustaining vs. palliative care. Finally, using regret DCA, the optimal decision for the specific patient is suggested.

Task 4: We are in the process of conducting a systematic review addressing the prognosis of metastatic lung cancer patients. We have finished the literature search and found 39 Randomized Controlled Trials (RCTs). We have extracted data for the outcomes of overall survival, type of treatment and patient characteristics etc. from these RCTs. We have calculated the pooled overall median survival of lung cancer patients from these RCTs. Similarly, we have calculated the pooled proportion of mortality among patients receiving no active treatment from the studies. Finally we are creating evidence tables for Lung cancer disease to use as inputs for the DEALE prognostication methodology.

Task 5: We have developed a pilot Chronic Pain Management Module to complement the CDSS-EBM. Our objective is to develop a reliable dosage conversion system as well as a knowledge based for each available pain medication. To that end, we have extracted data on dosage, cycles, route, duration, and time to peak effect for all available pain medications. In addition to the dosage conversion system, we have developed evidence-based web-based expert system for pain management based on the National Comprehensive Cancer Network guidelines. The system is currently going through the final programming phase and will be tested internally and in the clinic once we get the approval to begin clinical part of the study.

Key research accomplishments

- Development of case report for data extraction from Tampa Bay Lifepath Hospice Center's data.
- Developed decision curves for the SUPPORT prognostication model.
- Developed the first version of the Rough Set Theory prognostication model.
- Created a novel methodology that combines Decision Curve Analysis and Regret theory to compare multiple decision strategies based on the decision maker's personal attitudes towards each strategy.
- Developed a new method for elicitation of patient preferences
- Developed a pilot, web-based version of the CDSS-EBM for hospice referral.
- Created evidence tables for Lung cancer.
- Developed a pilot, web-based version of the chronic pain management module.

Reportable outcomes

1. Journal publication: (appendix 1)

A. Tsalatsanis, I. Hozo, A. Vickers, B. Djulbegovic. A regret theory approach to decision curve analysis: A novel proposal for elicitation of decision maker's preferences. Submitted to BMC Medical Informatics and Decision Making; Revisions stage,

2. Abstract presentation: (appendix 2)

I. Hozo, A. Tsalatsanis, A. Vickers, B. Djulbegovic. A regret theory approach to decision curve analysis. To be presented at SMDM annual meeting 2010.

Conclusion

We have already begun working on the majority of tasks described in the Statement of Work. We believe that we have closely followed the grant's timeline where we could control the work process. At this point, we are still working on fine-tuning theoretical aspects of our work, while waiting for the final approval of clinical part of the study. Once we obtain the approval from the HRPO office, we can start collecting retrospective data from Tampa Bay Life path hospice center and evaluate the performance of our prognostication models. Our research findings so far can be summarized as follows:

- Based on theoretical model, we found that deciding based on the SUPPORT prognostication model is the preferable strategy for a large range of threshold probabilities (8% to 91%) when compared to the strategies of referring all patients to hospice or referring no patients to hospice.
- We concluded that, regarding lung cancer, more investigation is needed to formally compare the predictive performances of SUPPORT and DEALE models.
- Based on the area under the curve measure, the RST model performs better than SUPPORT in patient classification. However, further investigation is required to determine the impact of reducing the number of variables utilized or the addition of qualitative variables such as physicians' values regarding hospice referral.

In the near future we intend to investigate further details regarding the development of the RST prognostication methodology and its application to both SUPPORT and hospice datasets. We are expecting a journal publication as a result of this effort. Our goal is develop the appropriate theoretical framework that will facilitate the hospice referral process based on outcomes of multiple prognostication models. Our plan is to develop evidence-based decision-support system that will help both better referral to hospice as well help with pain management. Ultimately, the usefulness of our system will depend how well it performs when tested in clinical setting.

Next Steps

Our immediate next step is to complete a retrospective phase of the study. Based on the results of the retrospective phase of the study, we will decide on the final site for the prospective phase of the study: Tampa General Hospital (TGH) or James A. Haley Veteran's hospital. TGH refers more patients to hospice and logistically would allow us faster completion of the study. In addition, if the retrospective phase shows that the gender is important for accurate prediction and the subsequent decision-making, we will then likely conduct study at TGH to preserve the generalizability of the results. Nevertheless, the final decision will be made after the retrospective phase of the study is completed.

References

- [1] Tsalatsanis A, Hozo I, Vickers A, Djulbegovic B. A regret theory approach to decision curve analysis: A novel proposal for elicitation of decision maker's preferences. Submitted to BMC Medical Informatics and Decision Making; Revisions stage.
- [2] Hozo I, Tsalatsanis A, Vickers A, Djulbegovic B. A regret theory approach to decision curve analysis. To be presented at SMDM annual meeting 2010.
- [3] The-Support-Investigators. A Controlled Trial to Improve Care for Seriously Ill Hospitalized Patients: The Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT). JAMA 1995, 247(20):1591-1598.
- [4] Vickers AJ, Elkin EB. Decision Curve Analysis: A Novel Method for Evaluating Prediction Models. Med Decis Making. November 1, 2006 2006;26(6):565-574.
- [5] Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (The "D.E.A.L.E").I. Validation of the method. Am J Med. 1982;73:883-888.
- [6] Lin TJ, Cercone N. Rough Sets and Data Mining, Analysis of Imprecise Data: Kluwer Academic Publishers; 1997.

A regret theory approach to decision curve analysis: A novel method for eliciting decision makers' preferences and decision-making

Athanasios Tsalatsanis¹, Iztok Hozo², Andrew Vickers³, Benjamin Djulbegovic^{1, 4, 5}

¹Center for Evidence-based Medicine and Health Outcomes Research, University of South Florida, Tampa, FL

²Department of Mathematics, Indiana University Northwest, Gary, IN

³Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, NY

⁴H. Lee Moffitt Cancer Center& Research Institute

⁵Corresponding author

Email addresses:

AT: atsalats@health.usf.edu

IH: ihozo@iun.edu

AV: vickersa@mskcc.org

BD: bdjulbeg@health.usf.edu

Abstract

Background

Decision curve analysis (DCA) has been proposed as an alternative method for evaluation of diagnostic tests, prediction models, and molecular markers. However, DCA is based on expected utility theory, which has been routinely violated by decision makers. Decision-making is governed by intuition (system 1), and analytical, deliberative process (system 2), thus, rational decision-making should reflect both formal principles of rationality and intuition about good decisions. We use the cognitive emotion of regret to serve as a link between systems 1 and 2 and to reformulate DCA.

Methods

First, we analysed a classic decision tree describing three decision alternatives: treat, do not treat, and treat or no treat based on a predictive model. We then computed the expected regret for each of these alternatives as the difference between the utility of the action taken and the utility of the action that, in retrospect, should have been taken. For any pair of strategies, we measure the difference in net expected regret. Finally, we employ the concept of acceptable regret to identify the circumstances under which a potentially wrong strategy is tolerable to a decision-maker.

Results

We developed a novel dual visual analog scale to describe the relationship between regret associated with “omissions” (e.g. failure to treat) vs. “commissions” (e.g. treating unnecessary) and decision maker’s preferences as expressed in terms of threshold probability. We then proved that the Net Expected Regret Difference, first presented in this paper, is equivalent to net benefits as described in the original DCA. Based on the concept of acceptable regret we identified the circumstances under which a decision maker tolerates a potentially wrong decision and expressed it in terms of probability of disease.

Conclusions

We present a novel method for eliciting decision maker’s preferences and an alternative derivation of DCA based on regret theory. Our approach may be intuitively more appealing to a decision-maker, particularly in those clinical situations when the best management option is the one associated with the least amount of regret (e.g. diagnosis and treatment of advanced cancer, etc).

Background

Decision making is often governed by uncertainty that inevitably affects the overall decision process. In their efforts to model uncertainty, decision theorists have proposed many methodologies with the majority of them having been based on statistics and probability[1-4], information theory and entropy[5], or possibilistic approaches such as fuzzy logic[6, 7].

In clinical medical research, much effort has been invested in developing decision support systems for diagnosis and treatment of various clinical conditions such as management of infectious diseases in an intensive care unit, chronic prostatitis, or liver surgery[8-12] to name a few examples. Most of these systems are based on probabilistic prediction models. Even though prediction models have been shown to be generally superior and potentially complementary to physicians' prognostications [13-15], historically they have not fulfilled decision makers' expectations to help improve decision-making. One reason for this is that most probabilistic medical decision support systems are based on expected utility theory that humans often violate[14, 16, 17]. In addition, most models in medicine do not incorporate decision-makers' preferences, which in addition to having reliable evidence, is the key to rational decision-making[18-20].

The goal of this paper is to develop a novel decision-making approach that incorporates the decision maker's attitudes towards multiple treatment strategies. Our goal is addressed through the following three specific aims. First, we deviate from the traditional expected utility theory in an attempt to satisfy both formal criteria of rationality and human intuition about good decisions[18-22]. We employ regret theory, since regret is a cognitive emotion that combines both rationality and intuition, which are key elements for decision-making[22, 23], to develop a novel methodology for eliciting decision makers' personal preferences. Consequently we reformulate decision curve analysis (DCA)[24, 25] from the regret theory point of view to evaluate alternative treatment strategies and to integrate both evidence on prognosis and treatment with the decision maker's attitudes and preferences[26-28]. Finally, we identify circumstances under which a decision maker tolerates a wrong decision.

To implement our approach, we first compute the threshold probability at which the decision maker is indifferent between alternative actions, based on the level of regret one might feel when he/she makes a wrong decision. We then employ the regret based DCA to identify the optimal strategy for a particular decision maker. The optimal strategy is the one that brings the least regret in the case that it is, in retrospect, wrong. We also show how to employ a prediction model to estimate the probability of disease for a patient and contrast it with the decision maker's threshold probability. Finally, we incorporate the concept of acceptable regret in the decision process to identify the conditions under which the decision maker tolerates a potentially wrong decision.

Methods

Decision analysis based on regret theory

Figure 1 depicts a typical decision tree describing administration of treatment guided by a prediction model. There are two competing strategies (treat, and do not treat), and four possible outcomes as described by the combinations: treat/ do not treat and necessary/unnecessary.

In Figure 1, $p = P(D +)$ is the probability associated with the presence of the disease as estimated by a prediction model; $1 - p = P(D -)$ is the probability associated with the absence of the disease, and $U_i, i \in [1, 4]$, are the utilities corresponding to each outcome. For example, U_1 is the utility of administering treatment to a patient who has

the disease (e.g. treat when necessary), and U_2 is the utility of administering treatment to a patient who does not have the disease (e.g. administering unnecessary treatment). Note that we use the term “treatment” in the generic sense of health care intervention, which may indicate therapy, procedure, or a diagnostic test.

The probabilistic nature of prognostication models complicates significantly the decision process. For example, if a prediction model estimates the probability of a patient having a disease equal to 40%, it is unclear whether this patient should receive treatment or not. A solution from the point of view of the classical decision theory is to employ the concept of threshold probability P_t , which is defined as the probability at which the decision maker is indifferent between two strategies (e.g. administer treatment or not)[27, 29, 30]. Based on the threshold concept, the patient should be treated if $p \geq P_t$ and should not be treated otherwise.

However, since in most cases decisions are made under uncertainty and can never be 100% accurate [23, 26, 28, 31-34]. Thus, after a decision has been made one may discover that another alternative would have been preferable. This knowledge may bring a sense of loss or regret to the decision maker[23, 26, 28, 31-34]. Regret can be particularly strong when the consequences of wrong decisions are life threatening or seriously influence the quality of the patient's life.

Formally, regret can be expressed as the difference between the utility of the outcome of the action taken and the utility of the outcome of the action that, in retrospect, should have been taken [23, 26, 28, 31-34]. Regret can be felt by any party involved in the decision-making process (e.g. patients receiving treatment, patient's proxies or physicians administering treatment). For the rest of this paper we assume that the decision maker is the treating physician.

We first employ regret theory to estimate the threshold probability, P_t , at which the physician is indifferent between alternative management strategies (e.g. administer treatment or not). In order to accomplish this, we describe regret in terms of the errors of (1) not treating the patient who has the disease, and (2) treating the patient who does not have the disease.

Figure 2 describes the derivation of regret associated with each strategy based on the utilities of each action's outcome. As can be noted, the regret associated with the error of not treating the patient when he/she should have received treatment (the probability of disease is $p \geq P_t$), $Rg(Rx-, D+)$, is equal to the loss in benefits of treatment. This can be expressed as the difference between the utility of receiving treatment and having the disease, and the utility of not receiving treatment and having the disease (U_1-U_3).

Similarly, the regret associated with treating the patient who should not have received treatment (the probability of disease is $p < P_t$), $Rg(Rx+, D-)$, is equal to harms incurred due to treatment. This can be expressed as the difference between the utilities of not having the disease and not receiving treatment, and not having the disease and receiving treatment (U_4-U_2). We expect no regret in the cases of correct treat/no treat decisions, $Rg(Rx+, D+) = Rg(Rx-, D-) = 0$. The difference (U_1-U_3) represents the consequences of not administering treatment where indicated, while (U_4-U_2) represents the consequences of administering treatment to a patient who does not need it. Under these assumptions, the threshold probability, P_t is equal to [27, 29, 30]:

$$P_t = \frac{1}{1 + \frac{U_1 - U_3}{U_4 - U_2}} \quad (1)$$

Equation 1 effectively captures the preferences of the decision maker towards administering or not administering treatment. At the individual level, equation 1 shows how the threshold probability relates to the way the

decision maker weighs false negative (i.e. failing to provide necessary treatment) vs. false positive (i.e. administering unnecessary treatment) results[24, 25].

Note that the fraction $\frac{U_1 - U_3}{U_4 - U_2}$ is undefined for $U_4 - U_2 = 0$, which means that in this situation there is no regret associated with administering unnecessary treatment. Under these circumstances, $P_t = 100\%$, indicating that treatment is justified only in case of absolute certainty of disease ($p=100\%$), a realistically unachievable goal[26].

Elicitation of threshold probability

There are numerous techniques for eliciting the decision maker's preferences regarding treatment administration [35]. None of them has been proven to be better than the other. We argue that any attempt to measure people's preferences and risk attitudes should be derived from an underlying theory of decision-making that can be applied to a problem or a class of the problems at hand. We approach elicitation of preferences by capturing people attitudes (e.g. physicians') through threshold probabilities. Normatively, a threshold probability reflects indifference between two alternative management strategies.

There are few commonly used methods to assess the value of this indifference for a decision maker such as the standard gamble, and the time trade-off [35-37]. The problem is that both standard gamble and time trade-off are time-consuming, cognitively more complex and are shown that can lead to biased estimates of people's preferences [36, 37]. An alternative method is to use rating scales, such as visual analog scales (VAS), which are considerably easier to administer and better understood by the participants. The problem with analog scales, however, is that they cannot capture health states trade-offs[36, 37].

The proposed method retains the simplicity of VAS but it takes into account the consequences of possible mistakes in decision-making by utilizing two visual analog scales. The first scale aims to assess the regret associated with potential error of failing to administer beneficial treatment ("regret of omission"). The second scale measures the regret of administration of unnecessary treatment ("regret of commission"). Using these two scales we can capture trade-offs and compute the threshold probability at which a decision maker is indifferent between two alternative management strategies.

We employed the two visual analog scales with typical 100 points [35-37] anchored by no regret and maximal regret. This is modeled after pain assessment limiting the maximum possible pain that a person can experience [38]. Accordingly, we can elicit threshold probabilities by asking the physician to weigh the regret associated with wrong decisions (e.g. giving unnecessary treatment vs. failure to administer necessary treatment) using a numerical (0 to 100) scale. The questions may be narrowly defined related to specific outcomes (e.g., survival/mortality, heart attack etc.). We should, however, note that most treatments are associated with multiple dimensions, some good and some bad. This is a fundamental reason why no universally accepted method for assessment of decision-makers' preferences has been developed so far. It is very difficult, if not impossible, to accurately determine the trade-offs across multiple outcomes that can be permuted in a number of ways. A solution to this problem is to capture the decision-maker's global or "holistic" perception toward treatment. By asking questions about trade-offs in this way, we directly address both cognitive mechanisms- intuitive and deliberative- of the decision process. This, in turn, can lead to more accurate assessment of the decision makers' preferences.

For example, to elicit the physician's threshold probability, we may ask the following questions:

1. *On a scale 0 to 100, where 0 indicates no regret and 100 indicates the maximum regret you could feel, how would you rate the level of your regret if you failed to provide necessary treatment to your patient (i.e. did not give treatment that, in retrospect, you should have given)?* [Note that the answer to this question corresponds to the (U1-U3) expression in equation 1)].
2. *On a scale 0 to 100, where 0 indicates no regret and 100 indicates the maximum regret you could feel, how would you rate the level of your regret if you had administered unnecessary treatment to your patient (i.e. administered treatment that, in retrospect, should have not been given)?* [Note the answer to this question corresponds to the (U4-U2) expression in equation 1).]

For example, suppose that the physician answers 60 and 30 to the questions 1 and 2, respectively. This means that the physician considers 60/30=2 times worse to fail to administer treatment that should have been given than to continue unnecessary treatment. Then, the threshold probability for this physician is:

$$P_t = \frac{1}{1 + \frac{U_1 - U_3}{U_4 - U_2}} = \frac{1}{3} = 33\%.$$

Thus, the physician would be unsure as to whether to treat or not the patient if the patient's probability of disease as computed by the prediction model was 33%. Thus, the recommended action, which is based on elicitation of the decision-maker preferences, is directly derived from the underlying theoretical model.

Regret based decision curve analysis (DCA)

Decision-makers may be presented with many alternative strategies that can be difficult to model. A simple, yet powerful approach that is based on experience of a typical practicing physician is to compare the strategy based on modeling with those scenarios when all or no patient is treated. That is, the clinical alternatives to the prediction model strategy is to assume that all patients have the disease and thus treat them all, or to assume that no patient has the disease and thus treat none[25]. In this case the clinical dilemma a physician faces when considering treatment is threefold: (1) treat all the patients ("treat all"), (2) treat no patients ("treat none"), and (3) use a prediction model and treat a patient if $p \geq P_t$ ("model").

The optimal decision depends on the preferences of the decision maker as captured by the threshold probability. We use Decision Curve Analysis (DCA) [24, 25] to identify the range of threshold probabilities at which each strategy ("treat all", "treat none", and "model") is of value. Traditional DCA uses the (net expected) benefits associated with each strategy to recommend the best strategy [24, 25]. In this work, we consider that the optimal strategy is the one that brings the least regret in case it is proven wrong, retrospectively.

One view about decision curves is that they should not be used in clinical practice: the researcher determines whether the decision curve justifies the use of the model in practice and then makes a simple recommendation yes or no as to whether clinicians should base their decisions on the model [39]. Another approach, which we propose here, is that threshold probabilities obtained in clinical practice should be compared against the decision curve to determine

which strategy should be used (e.g. use a model, biopsy all men, biopsy no-one). This might be necessary if there is no strategy with the highest net benefit across the entire range of reasonable threshold probabilities.

Figure 3, depicts the generalized decision tree describing all of the alternative strategies. By solving the decision tree, we can estimate the expected regret associated with each strategy[23, 26, 28, 31-34]. For example,

$$ERg[Model] = p(FN)(U_1 - U_3) + (1 - p)(FP)(U_4 - U_2) \quad (2)$$

Here, FN (probability of false negatives) represents the conditional probability $P(p < P_t | D +)$ of not treating the patient who has the disease.

FP (probability of false positives) is the conditional probability $P(p \geq P_t | D -)$ of treating the patient who does not have the disease.

Similarly,

$TP = 1 - FN = P(p \geq P_t | D +)$ (probability of true positives): Probability of treating the patient who has the disease.

$TN = 1 - FP = P(p < P_t | D -)$ (probability of true negatives): Probability of not treating the patient who does not have the disease.

After re-scaling the utilities by dividing each utility with the expression $U_1 - U_3$, and replacing $\frac{U_4 - U_2}{U_1 - U_3} = \frac{P_t}{1 - P_t}$, we get the expression:

$$\begin{aligned} ERg[Model] &= p(FN) + (1 - p)(FP) \frac{P_t}{1 - P_t} = p(1 - TP) + (1 - p)(FP) \frac{P_t}{1 - P_t} \\ &= P(p < P_t \cap D +) + P(p \geq P_t \cap D -) \frac{P_t}{1 - P_t} \end{aligned} \quad (3)$$

For the strategies of administering treatment and not administering treatment, the expected regret is derived as:

$$ERg[Treat\ all] = (1 - p)(U_4 - U_2) = (1 - p) \frac{P_t}{1 - P_t} \quad (4)$$

$$ERg[Treat\ none] = p(U_1 - U_3) = p \quad (5)$$

Subtracting each of these expected regrets from the expected regret of the “Treat none” (baseline) strategy we obtain the “**Net Expected Regret Difference (NERD)**”:

$$\begin{aligned} NERD[Treat\ none, Model] &= ERg[Treat\ none] - ERg[Model] = p - p(1 - TP) - (1 - p)(FP) \frac{P_t}{1 - P_t} \\ &= p(TP) - (1 - p)(FP) \frac{P_t}{1 - P_t} \end{aligned} \quad (6)$$

$$NERD[Treat\ none, Treat\ al] = ERg[Treat\ none] - ERg[Treat\ all] = p - (1 - p) \frac{P_t}{1 - P_t} \quad (7)$$

$$NERD[Treat\ none, Treat\ none] = 0 \quad (8)$$

Note that these are **exactly** the same formulas as those derived by Vickers and Elkin [25] who employ the expected-utility model in “decision curve analysis” (DCA). The regret based derivation, however, is mathematically more parsimonious. The original DCA formulation required several mathematical manipulations making the simplicity of regret approach more attractive. In addition, as argued throughout the manuscript, the regret formulation may have additional decision-theoretical advantages as it enables experiencing consequences of decisions both at the emotional (system 1) and cognitive (system 2) level[23, 40].

In addition to equations 6-8, we are interested in the NERD between the strategies “Treat all” and “Model”:

$$NERD[Treat\ all, Model] = ERg[Treat\ all] - ERg[Model] = (1 - p)(TN) \frac{P_t}{1 - P_t} - p(FN) \quad (9)$$

The NERD equations associated with each strategy, 6-8, can be further reformulated as follows[23, 25, 26, 28, 31-34, 41]:

$$NERD = P(p \geq P_t \cap D +) - P(p \geq P_t \cap D -) \frac{P_t}{1 - P_t} = \frac{\#TP}{n} - \frac{\#FP}{n} \cdot \frac{P_t}{1 - P_t} \quad (10)$$

Similarly, equation 9 can be re-written as:

$$NERD = (1 - p)(TN) \frac{P_t}{1 - P_t} - p(FN) = P(p < P_t \cap D -) \frac{P_t}{1 - P_t} - P(p < P_t \cap D +) = \frac{\#TN}{n} \cdot \frac{P_t}{1 - P_t} - \frac{\#FN}{n} \quad (11)$$

Equations 10 and 11 above are useful when calculating $NERD$ as a function of P_t . The probabilities $P(p \geq P_t \cap D +)$, $P(p \geq P_t \cap D -)$, $P(p < P_t \cap D +)$, and $P(p < P_t \cap D -)$ are estimated as follows:

- $P(p \geq P_t \cap D +) \approx$ the number of patients who have the disease and for whom the prognostic probability is greater than or equal to P_t (with $\#TP$ = number of patients with true positive results, $P(p \geq P_t \cap D +) \approx \frac{\#TP}{n}$, where n is the total number of patients in the study).
- $P(p \geq P_t \cap D -) \approx$ the number of patients who do not have the disease and for whom the prognostic probability of disease is greater than or equal to P_t (with $\#FP$ = number of patients with false positive results, $P(p \geq P_t \cap D -) \approx \frac{\#FP}{n}$).
- $P(p < P_t \cap D +) \approx$ the number of patients who have the disease and for whom the prognostic probability of disease is less than P_t (with $\#TN$ = number of patients with true negative results, $P(p < P_t \cap D +) \approx \frac{\#TN}{n}$).
- $P(p < P_t \cap D -) \approx$ the number of patients who do not have the disease and for whom the prognostic probability of disease is less than P_t (with $\#FN$ = number of patients with false negative results, $P(p < P_t \cap D -) \approx \frac{\#FN}{n}$).

When computing $NERD[Treat\ none, Treat\ all]$ we assume that all patients have the disease, thus $\#TP$ is the number of people who actually have the disease and $\#FP$ is the number of people who do not have the disease but are given treatment. On the other hand, when computing $NERD[Treat\ none, Model]$ from equation 10 and $NERD[Treat\ all, Model]$ from equation 11, $\#TP$, $\#FP$, $\#TN$, and $\#FN$ are computed for each threshold probability assuming that a patient has the disease if the prognostic probability is greater than or equal to the threshold probability and does not have the disease, otherwise.

NERDs of each of the strategies described are plotted against different values of threshold probability. The NERD values provide information relative to **decrease in regret** when two strategies are compared against each other for a given threshold probability. If $NERD=0$, this means that there is no difference in the regret between two strategies:

$$NERD[strategy\ 1, strategy\ 2] = 0 \Leftrightarrow \quad (12)$$

$$ERg(strategy1) - ERg(strategy2) = 0 \Leftrightarrow$$

$$ERg(strategy1) = ERg(strategy2)$$

If $NERD > 0$, this means that the second strategy will inflict less regret than the first strategy, and hence it is preferable:

$$NERD[strategy\ 1, strategy\ 2] > 0 \Leftrightarrow$$

$$ERg(strategy1) > ERg(strategy2)$$

(13)

Similarly, if $NERD < 0$, the first strategy represents the optimal decision among the two strategies:

$$NERD[strategy\ 1, strategy\ 2] < 0 \Leftrightarrow$$

$$ERg(strategy1) < ERg(strategy2)$$

(14)

The algorithm for the Regret DCA is implemented as follows:

1. Select a value for threshold probability.
2. Assuming that patients should be treated if $p \geq P_t$ and should not be treated otherwise, compute #TP and #FP for the prediction model.
3. Calculate the $NERD(Treat\ none, Model)$ using equation 10.
4. Calculate $NERD(Treat\ all, Model)$ using equation 11.
5. Compute the $NERD(Treat\ none, Treat\ all)$ using equation 10 where #TP is the number of patients having the disease and #FP is the number of patients without disease who got treatment.
6. Repeat steps 1 – 6 for a range of threshold probabilities.
7. Graph each NERD calculated in steps 3-5 against each threshold probability.

Based on the Regret DCA methodology, the optimal decision at each threshold probability is derived by comparing each pair of strategies through their corresponding NERDs according to the transitivity principle (i.e., if $A > B$, $B > C$ then $A > C$). Thus, if $NERD(strategy1, strategy2) > NERD(strategy2, strategy3) > 0$ then strategy 2 is better than strategy 1, and strategy 3 is better than strategy 2. Therefore, strategy 3 is the optimal strategy.

Acceptable Regret

No decision model can guarantee that the recommended strategy will be the correct one. Therefore, we can always make a mistake and recommend treatment we should not have, or fail to recommend treatment we should have administered [42]. However, there are situations where the regret resulting from a wrong decision will be tolerable. These situations are best described under the notion of acceptable regret [26, 28, 31]. Formally, acceptable regret, Rg_0 , is defined as the portion of utility a decision maker is willing to lose/sacrifice when he/she adheres to a decision that may prove wrong [26, 28, 31, 32]. For example, a physician may regret administering unnecessary treatment to a patient but he/she can “still live with” the consequences of this decision if she/he judged them to be trivial or inconsequential.

We assume that there is a linear relationship between the value of acceptable regret and the benefits of receiving treatment as well as the harms of receiving unnecessary treatment. This is a reasonable assumption because acceptable regret is expected to operate within a narrow range, at the lower or the upper end, of the probability scale.

We define acceptable regret in terms of benefits of treatment, Rg_b , as[43] the percentage (r_b) of benefits ($U_1 - U_3$) the decision maker is willing to forgo if his/her decision NOT to treat was wrong:

$$Rg_0 = Rg_b = r_b B = r_b (U_1 - U_3) \quad (15)$$

Alternatively, we define acceptable regret in terms of harms of unnecessary treatment, Rg_h , as[43] the percentage (r_h) of harms ($U_4 - U_2$) the decision maker is willing to incur if his/her decision of treating was wrong:

$$Rg_0 = Rg_h = r_h H = r_h (U_4 - U_2) \quad (16)$$

We use the concept of acceptable regret to further refine the conditions under which the decision maker is indifferent between two strategies. Recall that these conditions have been initially captured in terms of threshold probability, which does not incorporate the sense of tolerable losses. Thus, we proceed with the following definition:

Two strategies are considered *equivalent in regret* (e.g. will bring the same regret to the decision maker if they are proven wrong, in retrospect), if the absolute value of their net expected regret difference (NERD) is less than or equal to a predetermined amount of acceptable regret Rg_0 . In other words, there is no difference between choosing the strategy “treat all” or “treat none” in terms of regret if:

$$|NERD(Treat\ none, Treat\ all)| \leq Rg_0 \quad (17)$$

Similarly, the strategies “model” and “treat none” are equivalent in regret if:

$$|NERD(Treat\ none, Model)| \leq Rg_0 \quad (18)$$

and the strategies “model” and “treat all”:

$$|NERD(Treat\ all, Model)| \leq Rg_0 \quad (19)$$

The acceptable regret, Rg_0 , can be computed using any of the two definitions described in equations 15 and 16.

We can also use equations 15 and 16 to identify the prognostic probabilities at which the decision maker would not regret the decision to which he/she is committed even if that decision may prove wrong. For instance, we are typically interested in the prognostic probability above which a physician would commit to the decision to treat a patient, and the probability below which he/she would not to treat a patient without feeling undue consequences of these decisions[28]. In other words, we are looking for the probabilities for which $ERg(Treat\ all) \leq Rg_h$, and $ERg(Treat\ none) \leq Rg_b$. Solving the inequalities using equations 4, 5, 15, and 16 and after scaling Rg_0 by $(U_1 - U_3)$, we obtain

$$P_{treat\ all} = 1 - r_h \quad (20)$$

where $P_{treat\ all}$ is the prognostic probability above which the physician would tolerate giving treatment that may prove unnecessary. Similarly,

$$P_{treat\ none} = r_b \quad (21)$$

represents the prognostic probability below which the physician would comfortably withhold treatment that may prove beneficial, in retrospect.

Note that equations 20 and 21 express acceptable regret in terms of probabilities while equations 17-19 define it in terms of NERD. Hence, the outputs of these equations are not the same; rather, they complement each other.

Elicitation of acceptable regret

In most cases the decision maker does not have a complete understanding of benefits lost or harms inflicted and cannot assign a precise number to them. For this reason, we do not suggest inquiring directly about the value of r .

Instead, we propose eliciting r through the decision-maker's responses to specific clinical scenarios. For example, we propose the following approach (see Table 1 for the specific example):

*Assume that you have **100 patients with the same probability of disease as the patient you are currently treating**. You need to decide whether each of these patients should receive treatment or not. Since no prediction model is 100% accurate, it is expected that you will make some mistakes in your treatment recommendations (e.g. you may recommend treatment to a patient who does not need it, or fail to recommend treatment to a patient who needs it).*

1. *We are now interested in knowing your tolerance toward administering **unnecessary** treatment i.e. we want to learn what the magnitude of the **unavoidable error** you can live with is by inflicting potentially harmful treatment on a patient. Note that if you say that your acceptable regret is zero, this means that you can only make decision if you **absolutely certain** that your recommendation is correct.*

Out of the number $(100-y)$ of patients who should have not received treatment, how many patients would you tolerate treating? (The answer is used to compute r_h).

2. *We are interested in knowing your tolerance toward **failing** to provide necessary treatment i.e. we want to learn what the magnitude of **unavoidable error** you can live with is by forgoing potentially beneficial treatment. Note that if you say that your acceptable regret is zero, this means that you can only make decision if you **absolutely certain** that your recommendation is correct.*

Out of the number $(100-x)$ of patients who should have been treated, how many patients would you tolerate not treating? (The answer is used to compute r_b).

It is unnecessary to ask the decision maker to answer both questions. We suggest asking only the question related to the recommendation the physician is about to make e.g. if the recommendation is about administering treatment, then the decision maker should be asked the second question, while if it is about not giving treatment, then he/she can ask the first question.

The value of acceptable regret is plotted in the regret DCA graph to visually facilitate the decision making process. At a specific threshold probability all strategies for which $|NERD| \leq Rg_0$ are considered equivalent in regret, according to the definition in the previous section.

Example

We will employ a prostate cancer biopsy example to demonstrate the applicability of our approach. Prostate cancer biopsy is an invasive and uncomfortable procedure, which can be painful and is associated with a risk of infection. However, it is often necessary for diagnosis of prostate cancer, one of the leading causes of cancer death in men.

Men are typically biopsied for prostate cancer if they have an elevated level of prostate-specific antigen (PSA). However, most men with a high PSA do not have prostate cancer. This has led to the idea that statistical models based

on multiple predictors (PSA, age, family history, other markers) might be used to predict biopsy outcomes and hence aid biopsy decisions for individual patients. A physician seeing a patient with an elevated PSA has three possible options: go for biopsy, refuse biopsy or look up his probability in a statistical model and then make a decision.

We utilize an unpublished statistical model that computes probability of cancer based on the dataset described in [44] to compare each of these options. Following the algorithm described in the regret DCA section, we generate the decision curves depicted in Figure 4. This figure is used to determine the optimal strategy for different values of threshold probability. The optimization procedure is implemented in three steps where the strategies in each NERD are compared to each other as in equations 12- 14 at a specific threshold probability. For example, at threshold probability 15%:

1. $NERD(biopsy\ none, model) > 0$ therefore, the model is preferred to the strategy biopsy none.
2. $NERD(biopsy\ none, biopsy\ all) > 0$ therefore, the strategy biopsy all is preferred to the strategy biopsy none.
3. $NERD(biopsy\ all, model) > 0$ therefore, the model is preferred to the strategy biopsy none

Consequently, “model” corresponds to the optimal strategy.

Repeating the same procedure for all threshold probabilities, we can see that deciding based on the statistical model is the optimal strategy (i.e. results in the minimum expected regret) for threshold probabilities between 8% and 43%. For threshold probabilities between 42% and 95%, the optimal strategy is to biopsy no patients, while for 0% to 8% both model and biopsy all strategies are optimal.

To interpret these results, we have to consider how a typical physician values the harms of a false negative (missing a cancer) and a false positive (an unnecessary biopsy) result. If regret associated with unnecessary biopsy is felt to be worse than missing cancer, then according to equation 1, the threshold probability is greater than 50%. However, it is unlikely that a physician would consider an unnecessary biopsy to be worse than missing a cancer, so the threshold probability for biopsy must be less than 50%. Thus, a reasonable range of threshold probabilities might indeed be between 8% - 43% as suggested by our model. As the model is superior across this entire range, we can conclude that, **irrespective of the physician’s exact preferences**, making a biopsy decision based on the statistical model will lead to lower expected regret than an alternative such as biopsying all or no men. Based on discussions with clinicians, we believe that a reasonable range of threshold probability is 10% - 40%. As the regret associated with the model strategy is lowest across this entire range, we can recommend use of the model. Nonetheless, we do not have a complete sample of all physician preferences and it is possible that a physician may have a probability outside of this range.

To illustrate the applicability of the acceptable regret model, assume that the value of acceptable regret for forgoing the benefits of biopsy (equation 15) is equal to ± 0.01 . Consider the case that the decision maker’s threshold probability is equal to 20%. According to Figure 4, the optimal strategy should be suggested by the statistical model. However, we see that

$$|NERD(treat\ none, model)| < 0.01$$

which means that the strategies “biopsy none” (biopsy no patients) and “model” are equivalent in regret. Therefore, the prediction model does not offer any better information and thus, it can be disregarded.

Table1 describes the overall decision process regarding prostate cancer biopsy. The process begins with elicitation of the threshold probability from the treating physician and continues with evaluation of the available

strategies based on regret DCA (Figure 4). Based on the optimal strategy suggested by the regret DCA, the cancer probability is estimated. Finally, the optimal strategy is verified under the concept of acceptable regret. The normal font text corresponds to the author comments. The text in italic and bold font corresponds to questions to, and answers from the physician respectively. The underlined text is notes to the reader. We demonstrate the applicability of our approach using hypothetical answers from two physicians.

Discussion

Currently, there is no agreed upon method for how preferences regarding multiple objectives that typically go in opposite directions (i.e. most medical interventions are associated both with benefits and harms) should be elicited. We have presented and demonstrated an approach to decision making based on regret theory and decision curve analysis. The approach presented in this paper relies on the concept of the threshold probability at which a decision maker is indifferent between strategies, to suggest the optimal decision [27, 29, 30]. Unlike the approaches described in the classic threshold papers [27, 29, 30], our approach is based on the notion that the value of threshold probability is clearly subjective and depends on the personal preferences of the decision maker. We elicit threshold probabilities based on the regret one may feel in case that the chosen strategy is proven wrong, in retrospect. Although one can narrow down the approach to specific medical outcomes, we believe that eliciting preferences in a global, holistic way is more useful if our approach is to be used in the actual practice.

We believe that the model described here has a direct practical application in overcoming many difficulties related to linking evidence with patient's preferences to arrive at the optimal decision- the issues that plagued the field of decision-making. The problem of eliciting preferences and integrating them in a coherent decision is not a simple one. We argue that the approach we are advocating here represents a contribution to the field of decision making, be should not be seen as the panacea to medical decision making. However, we anticipate our methodology to be suitable for medical decision primarily associated with trade-offs between quality and quantity of life.

Over that last couple of decades, many attempts have been made to develop the best method to take these considerations in real-life settings. Unfortunately, as explained, no approach has succeeded [35]. We believe that the reason for this is that most approaches to elicit decision maker's preferences as well as to help improve decision-making have relied on a rational framework based on expected utility theory[21]. However, modern cognitive theories (within so called dual-processing theory) have convincingly demonstrated that human decisions rely both on intuition (system 1) and analytical, deliberative process (system 2) in balancing risks and benefits in the decision-making process [22 , 40 , 45]. We believe that rational decision-making should take into account both formal principles of rationality and human intuition about good decisions [46, 47]. The key is to preserve rational framework, while allowing anticipation of the effect of decision on emotions (while avoiding biases associated with intuitive thinking) [40]. One way to accomplish this is to use the cognitive emotion of regret to serve as a link between system 1 (i.e. intuitive system) and system 2 (i.e. deliberative, analytical cognitive system). By anticipating consequences of our actions and circumstances under which we can live with our mistakes, we bring together both aspects of cognition that may lead to better and more satisfactory decision-making.

Specifically, we argue that eliciting people's preferences using regret theory may be superior to using traditional utility theory because regret forces decision-makers to explicitly consider consequences of decisions. We have previously shown that we can always make errors in decision-making: recommend treatment that does not work, or fail to recommend treatment that does [26]. Therefore, we reformulated DCA from the regret theory's point of view. Furthermore, it has been shown that the expected utility theory is often violated to minimize anticipated regret [33,

34]. In addition, there is substantial evidence that medical decision making aims to minimize regret associated with wrong decisions [48-50].

Moreover, while descriptive, normative, and prescriptive theories [17] tend to evaluate individual outcomes, the approach presented here evaluates all of the outcomes in a holistic manner. Our approach is consistent with Reyna's "gist" or "fuzzy trace theory" in which the decision-maker characterizes gist of each outcome to arrive at a given decision [51]. For example, consider that a decision maker is provided with a list of harms and benefits associated with each decision, as it is currently recommended by the practice guidelines panels [52]. In traditional theories, the decision maker evaluates a treatment strategy by reasoning on each of the harms and benefits associated with a given strategy. This, as discussed above, would mean integration of all multiple outcomes that often go in different directions typically within limited time-frame. Due to the complexity of these decisions, however, this approach overwhelms the decision maker as our brain capacity is limited. The regret DCA methodology quantifies the global attitudes of the decision maker towards a specific strategy without requiring separate reasoning for each of the harms and benefits. This holistic assessment occurs within the dual processing cognitive system, which evaluates collectively the harms and the benefits associated with each treatment alternative. By assessing trade-offs through both cognitive mechanisms-intuitive and deliberative- we believe that we can assess decision makers' preferences more accurately.

In general, since our method relies on the elicitation of threshold probability we recommend using our methodology for every patient. As every patient's values are different the threshold probability should indeed be patient- specific. For example, a physician may act "aggressively" for a young patient who is the father of two underage kids and less aggressively for an older patient. However, in the cancer biopsy example, it is expected that most of the patients should present with similar characteristics and therefore most physicians would settle in a small area of threshold probabilities. In this case repeating the elicitation process for every patient would be impractical. Nevertheless, this is an empirical question worthy of further investigation as alluded above.

Our approach may help reconcile formal principles of rationality and human intuitions about good decisions that may better reflect "rationality" in medical decision-making [21, 32, 46, 47]. We hope that our theoretical work will stimulate empirical testing of the concepts outlined in this paper. Toward this end, we are currently working on developing a prescriptive computerized decision-support system to facilitate the application of the model described herein. Such a system is expected to be user friendly with built-in automatic manipulation of the complex calculations that may be off-putting to many users. We hope to report on testing of our system in the near future.

Conclusions

We have presented a decision making methodology that relies on regret theory and decision curve analysis to assist physicians in choosing between appropriate health care interventions. Our methodology utilizes the cognitive emotion of regret to determine the decision maker's preferences towards available strategies and DCA to suggest the optimal decision for the specific decision maker. We believe that our approach is suitable for those clinical situations when the best management option is the one associated with the least amount of regret (e.g. diagnosis and treatment of advanced cancer, etc).

As with any other novel theoretical work, our approach has its limitations. First, it has not been empirically tested in a clinical setting. However, we are in the process of developing the appropriate decision support tools to bring our model into clinical practice and evaluate its usefulness with actual physicians and patients. Second, the methodology presented is appropriate for single point decision making. Further investigation is required to determine the application of regret theory to decisions that re-occur over time. Finally, we assume that there is only one decision maker involved

in the decision process. Nevertheless, our plan for future work includes extending our methodology to shared decision-making that will include both physician and patient in the decision process and investigate whether in practice there is a difference between preferences and choices made by physicians and their patients.

We summarize the contribution presented in this paper as follows:

1. We propose a novel method for eliciting decision makers' preferences towards treatment administration.

Contrary to traditional methodologies on eliciting preferences, our method considers the consequences of potential mistakes in decisions. We propose a dual visual analog scale to capture errors of omission and errors of commission and, therefore, evaluate the trade-offs associated with each of the available strategies.

2. We have reformulated DCA from the regret theory point of view. Our approach is intuitively more appealing to a decision maker and should facilitate decision making particularly in those clinical situations when the best management option is the one associated with the least amount of regret.

3. Finally, we utilize the concept of acceptable regret to identify the circumstances under which a decision maker tolerates a wrong decision.

We envision facilitation of the decision process in clinical settings through a computerized decision support system available at the point of care. In fact, we are in the process of developing such a system and hope to report about it soon.

List of abbreviations

DCA: Decision Curve Analysis

NERD: Net Expected Regret Difference

VAS: Visual Analog Scale

Glossary

p	Prognostic probability
P_t	Threshold probability
$D + / D -$	The patient has/ does not have the disease
U_i	Utility corresponding to outcome i
$Rg(x)$	Regret associated with the action x
$Rx + / Rx -$	Treatment / No treatment
$U_1 - U_3$	Consequences of not administering treatment where indicated
$U_4 - U_2$	Consequences of unnecessarily administering treatment
$ERg(action)$	Expected regret associated with an action

TP, TN, FP, FN	Conditional probabilities
$\#TP, \#TN, \#FP, \#FN$	Number of TP, TN, FP, FN patients
n	Number of patients
$NERD(action1, action2)$	Net expected regret difference between actions 1 and 2
Rg_0	Acceptable regret
Rg_b	Acceptable regret as defined in terms of losses in benefits due to forgoing treatment
Rg_h	Acceptable regret as defined in terms of harms due to undergoing unnecessary treatment
r_b / r_h	Percentages of the benefits/harms a decision maker is willing to lose/incur in case of a wrong decision
$P_{treat\ all}$	The prognostic probability above which the decision maker would tolerate recommending unnecessary treatment.
$P_{treat\ none}$	The prognostic probability below which the decision maker would tolerate not recommending treatment.

Competing interests

The authors have no financial competing interests to declare.

Authors contributions

AT prepared the first draft, formalized the proposed methodology, and applied it into treatment administration examples; IH developed the mathematical formulation of the model; AV is the author of DCA; BD proposed the regret theory extension to DCA. All authors contributed equally in reviewing multiple versions of the paper and provided important feedback to the final version of the paper. BD is a guarantor.

Acknowledgements

This work is supported by the Department of Army grant #W81 XWH 09-2-0175.

References

1. Edwards W, Miles RFJ, von Winterfeldt D: **Advances in decision analysis. From foundations to applications.** New York: Cambridge University Press; 2007.
2. Lindley D: **Making decisions, 2nd edition.** New York: Willey; 1985.
3. Greenland S: **Probability logic and probabilistic induction.** *Epidemiology* 1998, **9**:322-332.
4. Greenland S: **Bayesian Interpretation and Analysis of Research Results.** *Seminars in Hematology* 2008, **45**(3):141-149.
5. Shannon C, Weaver W: **The mathematical theory of communication.** Urbana: The University of Illinois Press; 1962.
6. Zimmerman H: **Fuzzy set theory and its applications. 3rd edition.** Boston: Kluwer Academic Press; 1996.

7. Zimmerman H: **An application-oriented view of modelling uncertainty.** *European Journal of Operational Research* 2000, **122**:190-198.
8. Schurink CAM, Lucas PJF, Hoepelman IM, Bonten MJM: **Computer-assisted decision support for the diagnosis and treatment of infectious diseases in intensive care units.** *The Lancet Infectious Diseases* 2005, **5**(5):305-312.
9. Hansen C, Zidowitz S, Hindennach M, Schenk A, Hahn H, Peitgen HO: **Interactive determination of robust safety margins for oncologic liver surgery.** *International journal of computer assisted radiology and surgery* 2009, **4**(5):469-474.
10. Bratchikov OP, Korenevskii NA, Seregin SP, Dolzhenkov SD, Shumakova EA, Kotsar AG, Kriukov AA, Krivovtsev SI, Popov AV: **Automatic decision support system in prognostication, diagnosis, treatment and prophylaxis of chronic prostatitis.** *Urologiia* 2009(4):44-48.
11. Bertsche T, Askoxylakis V, Hahl G, Laidig F, Kaltschmidt J, Schmitt SP, Ghaderi H, Bois AZ, Milker-Zabel S, Debus J *et al*: **Multidisciplinary pain management based on a computerized clinical decision support system in cancer pain patients.** *Pain* 2009, **147**(1-3):20-28.
12. Rahilly-Tierney CR, Nash IS: **Decision-making in percutaneous coronary intervention: a survey.** *BMC Med Inform Decis Mak* 2008, **8**:28.
13. Dawes RM, Faust D, Meehl PE: **Clinical versus actuarial judgment.** *Science* 1989, **243**(4899):1668-1674.
14. Hastie R, Dawes RM: **Rational choice in an uncertain world.** London: Sage Publications, Inc.; 2001.
15. The-Support-Investigators: **A Controlled Trial to Improve Care for Seriously Ill Hospitalized Patients: The Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT).** *JAMA* 1995, **274**(20):1591-1598.
16. Baron J: **Thinking and deciding, 3rd ed.** Cambridge: Cambridge University Press; 2000.
17. Bell DE, Raiffa H, Tversky A: **Decision making. Descriptive, normative, and prescriptive interactions.** Cambridge: Cambridge University Press; 1988.
18. Djulbegovic B: **Lifting the fog of uncertainty from the practice of medicine.** *Bmj* 2004, **329**(7480):1419-1420.
19. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schunemann HJ: **Going from evidence to recommendations.** *Bmj* 2008, **336**(7652):1049-1051.
20. O'Connor AM, Legare F, Stacey D: **Risk communication in practice: the contribution of decision aids.** *Bmj* 2003, **327**(7417):736-740.
21. Djulbegovic B, Hozo I: **Health care reform & criteria for rational decision-making.** In: http://www.smdm.org/newsletter/spring_2010/#a22. 2010.
22. Slovic P, Finucane ML, Peters E, MacGregor DG: **Risk as analysis and risk as feelings: Some thoughts about affect, reason, risk, and rationality.** *Risk Analysis* 2004, **24**(2):311-321.
23. Zeelenberg M, Pieters R: **A theory of regret regulation 1.1.** *J Consumer Psychol* 2007, **17**:29-35.
24. Vickers A, Cronin A, Elkin E, Gonen M: **Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers.** *BMC Medical Informatics and Decision Making* 2008, **8**(1):53.
25. Vickers A, Elkin E: **Decision curve analysis: a novel method for evaluating prediction models.** *Med Dec Making* 2006, **26**(6):565-574.

26. Djulbegovic B, Hozo I: **When Should Potentially False Research Findings Be Considered Acceptable?** *PLoS Med* 2007, **4**(2):e26.
27. Djulbegovic B, Hozo I, Lyman GH: **Linking evidence-based medicine therapeutic summary measures to clinical decision analysis.** *MedGenMed* 2000, **2**(1):E6.
28. Djulbegovic B, Hozo I, Schwartz A, McMasters KM: **Acceptable regret in medical decision making.** *Med Hypotheses* 1999, **53**(3):253-259.
29. Pauker SG, Kassirer JP: **Therapeutic decision making: a cost-benefit analysis.** *N Engl J Med* 1975, **293**(5):229-234.
30. Pauker SG, Kassirer JP: **The threshold approach to clinical decision making.** *N Engl J Med* 1980, **302**(20):1109-1117.
31. Hozo I, Djulbegovic B: **When is diagnostic testing inappropriate or irrational? Acceptable regret approach.** *Med Dec Making* 2008, **28**(4):540-553.
32. Hozo I, Djulbegovic B: **Will insistence on practicing medicine according to expected utility theory lead to an increase in diagnostic testing?** *Med Dec Making* 2009, **29**:320-322.
33. Bell DE: **Regret in Decision Making under Uncertainty.** *Operations Research* 1982, **30**:961-981.
34. Loomes G, Sugden R: **Regret theory: an alternative theory of rational choice.** *Economic J* 1982, **92**:805-824.
35. Lichtenstein S, Slovic P: **The construction of preference.** New York: Cambridge University Press; 2006.
36. Stiggelbout AM, de Haes JC: **Patient preference for cancer therapy: an overview of measurement approaches.** *J Clin Oncol* 2001, **19**(1):220-230.
37. Hunnik M, Glasziou P: **Decision-making in health and medicine. Integrating evidence and values.** Cambridge: Cambridge University Press; 2001.
38. McCaffery M, Beebe A: **Pain: Clinical manual for nursing practice.** Baltimore: V.V. Mosby Company; 1993.
39. Steyerberg EW, Vickers AJ: **Decision curve analysis: a discussion.** *Med Decis Making* 2008, **28**(1):146-149.
40. Evans TSBT: **Hypothetical Thinking: Dual Processes in Reasoning and Judgement (Essays in Cognitive Psychology).** New York: Psychology Press: Taylor and Francis Group; 2007.
41. Peirce CS: **The numerical measure of the success of predictions.** *Science* 1884, **4**:453-454.
42. Djulbegovic B, Frohlich A, Bennett CL: **Acting on imperfect evidence: How much regret are we ready to accept?** *J Clin Oncol* 2005, **23**(28):6822-6825.
43. Hozo I, Schell MJ, Djulbegovic B: **Decision-Making When Data and Inferences Are Not Conclusive: Risk-Benefit and Acceptable Regret Approach.** *Seminars in Hematology* 2008, **45**(3):150-159.
44. **Decision curve analysis** [www.decisioncurveanalysis.org]
45. Kahneman D: **Maps of bounded rationality: psychology for behavioral economics.** *American Economic Review* 2003, **93**:1449-1475.
46. Krantz DH, Kunreuther HC: **Goals and plans in decision making** *Judgement and decision making* 2007, **2**(3):137-168.

47. Rawls J: **A theory of justice. Revised edition.** Cambridge: Harvard University Press; 1999.
48. Feinstein AR: **The 'chagrin factor' and qualitative decision analysis.** *Archives of internal medicine* 1985, **145**(7):1257-1259.
49. Le Minor M, Alperovitch A, Knill-Jones RP: **Applying decision theory to medical decision-making--concept of regret and error of diagnosis.** *Methods of information in medicine* 1982, **21**(1):3-8.
50. Hilden J, Glasziou P: **Regret graphs, diagnostic uncertainty and Youden's Index.** *Statistics in medicine* 1996, **15**(10):969-986.
51. Reyna V: **How people make decisions that involve risk: a dual-processes approach.** *Current Directions in Psychological Sciences* 2004, **13**:60-66.
52. GRADE-working-Group: **Grading quality of evidence and strength of recommendations.** *BMJ* 2004, **328**:1490-1498.

Figures




Figure 1. Decision tree for treatment distribution.

In this figure, $p = P(D +)$ is the probability associated with the presence of a disease; $1 - p = P(D -)$ is the probability associated with the absence of the disease; $U_i, i \in [1,4]$, are the utilities corresponding to each outcome. Note that we use the term “treatment” in the generic sense of health care intervention, which may indicate therapy, procedure, or a diagnostic test.




Figure 2. Regret model of decision tree treating a patient.

In this figure, p : probability of having the disease; $1-p$: probability of not having the disease; P_t : threshold probability for treatment; R_g : regret associated with wrong decisions; $Rx-$: no treatment; $Rx+$: treatment; $D+$: disease is present; $D-$: disease is absent. For example, $R_g(Rx+, D-)$: regret associated with the error of treating the patient who did not have the disease.




Figure 3. Generalized decision tree for administration of treatment.

In this figure, p : probability of having the disease; $1-p$: probability of not having the disease; R_g : regret associated with wrong decisions; $Rx-$: no treatment; $Rx+$: treatment; $D+$: disease is present; $D-$: disease is absent.




Figure 4. Regret DCA regarding biopsy to detect prostate cancer.

Thin line: biopsy all patients; solid line: biopsy no patients; dashed line: prediction model. The optimal strategy is derived by the comparison of each pair of strategies from all NERDs as per equations 12-14. The statistical model is the optimal strategy for threshold probabilities between 8% and 42%. For threshold probabilities between 43% and 95%, the optimal strategy is to biopsy no patients, while for 0% to 8% both “model” and “biopsy all” strategies are optimal. The lines of acceptable regret denote the regret area in which different strategies are equivalent. For example, at threshold probability equal to 20%, the optimal strategy is acting based on the prognostic model. However, $NERD(biopsy\ none, model)$ is below the acceptable regret line which indicates that the strategies “biopsy none” and “model” are equivalent in regret. Therefore the optimal strategy is to biopsy no patients as the use of model is deemed to be superfluous. Similarly, at threshold probability equal to 15%, the optimal strategy is to act based on the model and the strategies “biopsy all” and “biopsy none” are equivalent in regret. Finally, at threshold probability equal to 9%, the optimal strategies are both “model” and “biopsy all”. However, since $NERD(biopsy\ all, model)$ is below the acceptable regret, the strategies “biopsy all” and “model” are equivalent in regret. Therefore the optimal strategy is to biopsy all patients.

Tables

Table 1. Example: Decision process regarding prostate cancer biopsy.

The normal font text corresponds to the author comments. The text in *italic and bold font* corresponds to questions to and answers from the physicians, respectively. The underlined text is notes to the reader. We examine the problem from the perspective of two different (hypothetical) physicians.

1. Interview with the physician to elicit his/her threshold probability.

a. On the scale 0 to 100, where 0 indicates no regret and 100 indicates the maximum regret you could feel, how would you rate your level of regret if you failed to provide necessary treatment?

Physician #1 answer: 50, Physician #2 answer: 70. This value corresponds to $U_1 - U_3$ from equation 1.

b. On the scale 0 to 100, where 0 indicates no regret and 100 indicates the maximum regret you could feel, how would you rate your level of regret if you administered unnecessary treatment?

Physician #1: 10, Physician #2: 60. This value corresponds to $U_4 - U_2$ from equation 1.

The threshold probability is equal to (equation 1): Physician #1: 16%, Physician #2: 46%.

2. Using the graph in Figure 4, identify the optimal strategy for the computed threshold probability.

Physician #1: For threshold probability equal to 16%, the optimal decision is derived by solving the inequalities (Figure 4, equations 12-14):

1. $NERD(biopsy\ all, model) > 0$, the strategy “model” is better than the strategy “biopsy all”
2. $NERD(biopsy\ none, model) > 0$, the strategy “model” is better than the strategy “biopsy none”
3. $NERD(biopsy\ none, biopsy\ all) > 0$, the strategy “biopsy all” is better than “biopsy none”.

Therefore, the optimal strategy is the “model” which corresponds to biopsy based on the probability of cancer predicted by the statistical model. The next step will be to compute the patient’s probability of cancer and contrast it with the threshold probability.

Physician #2: For threshold probability equal to 46%, the optimal decision would be the “biopsy none” strategy. In this case, even though computing the probability of cancer will not affect the physician’s decision, it will help identify the circumstances under which the physician would tolerate unnecessary biopsy of the patient.

3. Compute the cancer probability for the specific patient based on the statistical model.

- a. If the cancer probability is greater than or equal to the threshold probability, then the surgeon should biopsy the patient.
- b. If the cancer probability is less than the threshold probability, then the surgeon should not biopsy the patient.

Let us assume that the probability of cancer for the specific patient is equal to 20%. The threshold probability for Physician #1 is 16% (as computed in step 1). In this case, Physician #1 considers recommending biopsy. As noted in step 2b, the best strategy for Physician #2 is recommending not to biopsy any patients regardless their probability of cancer.

4. Elicitation of the level of acceptable regret.

Assume that you have 100 patients, all with probability of cancer equal to 20% (the same as your patient). This means that out of 100 patients, 20 patients will have cancer while 80 will not have cancer. You need to decide whether each of these patients should undergo biopsy or not. Since no prediction model is 100% accurate, it is expected that you will make some mistakes in your recommendations (e.g. you may recommend biopsy to a patient who does not need it, or fail to recommend biopsy to a patient who may need it).

a. The physician considers biopsy (Physician #1):

Out of the 20 patients who should be biopsied, for how many patients would you tolerate not recommending a necessary biopsy? 1.

This answer corresponds to $r_b = \frac{1}{20} = 0.05$ and acceptable regret

$Rg_b = r_b(U_1 - U_3) = 0.05 * 0.5 = 0.025$. The optimal strategy at $P_t = 16\%$ is to use the statistical model (Figure 4). For $P_t = 16\%$ and $Rg_b = 0.025$, all NERDs are greater than acceptable regret, thus the optimal strategy remains the statistical model.

- b. The physician does not consider biopsy (Physician #2).

Out of the 80 patients who should not undergo biopsy, for how many patients would you tolerate recommending an unnecessary biopsy? 40.

The answer provided by the Physician #2 corresponds to $r_h = \frac{40}{80} = 0.50$ and acceptable regret

$$Rg_h = r_h(U_4 - U_2) = 0.5 * 0.6 = 0.3.$$

The optimal strategy for $P_t = 46\%$ is to biopsy no patients (Figure 4). Also, for $P_t = 46\%$ and $Rg_h = 0.3$, we have: $|NERD(biopsy\ none, biopsy\ all)| = |-0.639| > Rg_h$, $|NERD(biopsy\ none, model)| = |-0.003| < Rg_h$ and $NERD(biopsy\ all, model) = 0.6364 > Rg_h$. This means that the strategies “biopsy none” and “model” are equivalent in regret. In practical terms no additional effort is justified for using the statistical model.

5. Based on equations 20 and 21, we can determine the prognostic probabilities above and under which the physician would tolerate performing an unnecessary biopsy, or not to do so when he should have done it.

- a. Physician #1 considers recommending biopsy to his/her patient. Based on equation 21, the physician would tolerate not recommending a biopsy for any prognostic probability below

$$P_{treat\ none} = r_b = 5\%.$$

- b. Physician #2 considers not recommending biopsy to his/her patient. Based on equation 20, the decision maker would tolerate recommending an unnecessary biopsy for any prognostic probability above $P_{treat\ all} = 1 - r_h = 50\%$.

Appendix 2

A regret theory approach to decision curve analysis

Iztok Hozo¹, Athanasios Tsalatsanis², Andrew Vickers³, Benjamin Djulbegovic^{2,4}

¹Indiana University, ²University of South Florida, Center for Evidence-based Medicine, ³Memorial Sloan Kettering Cancer Center, NY and H. ⁴Lee Moffitt Cancer Center & Research Institute, Tampa, FL

Purpose: Decision curve analysis (DCA) has been proposed as an alternative method for evaluation of diagnostic tests, prediction models, and molecular markers [MDM 2006;26:565]. We re-formulated DCA from the regret theory point of view to take into consideration decision consequences [MDM 2008;28:540].

Methods: First, we constructed a classic decision tree describing three decision alternatives: treat, do not treat, and treat/no treat based on a predictive model. We then computed the expected regret for each of these alternatives as the difference between the utility of the action taken and the utility of the action that should have been taken, in retrospect. We evaluated the expected regret(s) for the tree using different weightings regarding regret associated with “omissions” (e.g. failure to treat) vs. “commissions” (e.g. treating unnecessary). For any pair of strategies, we measure the difference in net expected regret (NERD), by

subtracting the expected regret of each alternative from the other. Finally, using the concept of acceptable regret-the range at which potential regret associated with wrong decisions becomes acceptable- we identified the circumstances where acting on a given strategy will be acceptable even if the decision was wrong.

Results: We first showed that NERD is equivalent to net benefits as described in the original DCA. The regret re-formulation of the original DCA model showed an asymmetry in decision-making. That is, the decision-maker seems to weigh (=the threshold probability at which a decision-maker is indifferent between two actions) regret associated with failure to treat much higher than the regret related to unnecessary treatment. This is because the decision-maker weights true positive results to a much greater extent than false-positive results. Similarly, different attitudes toward omissions vs. commissions identified different circumstances when the decision-maker can “live with” regret even if the decision was wrong, in retrospect. The symmetry in the decision-making was re-instated when the weighting for false-positive and false-negative results was identical.

Conclusions: We present an alternative derivation of the DCA based on regret theory. Under assumptions of unequal weighting, the regret approach generates identical results to the original DCA. The regret approach may also be intuitively more appealing to a decision-maker, particularly in those clinical situations when the best management option is the one associated with the least amount of regret (e.g. treatment of advanced cancer, etc).

Appendix 3

Study ID #	
Hospice ID #	

Development of EBM-CDSS (Evidence-Based Clinical Decision Support System) to aid prognostication in terminally ill patients
--

Demographics	
Date of Birth	Date of Death
Gender (please check one)	Male
	Female
Ethnicity (please check one)	White
	African American
	Hispanic
	Asian
	Pacific islander
	Other:
Date of Hospice admission	
Referring institution	
Primary diagnosis	
Date of diagnosis	
Physician's prediction of survival (Please check one)	Hours-days
	Days-weeks
	< 6 months
	< 12 months (Private Pay1)
Patient directives (Please check one)	Do Not Resuscitate (DNR)
	Full code
Day in the hospital when qualified for study <i>(please circle one)</i>	1 2 3 4 5 6 7 8 9 10
Number of days in the hospital	
Length of follow up	Days

Vital Signs	Date Collected
Mean Arterial Blood Pressure	mmHg
Body temperature	°F
Heart rate	Beats/minute
Respiratory Rate	Breaths/minute

Laboratory Data	Date collected
Serum Creatinine	mg/dl
Serum Bilirubin	mg/dl
Serum Sodium	mEq/lt
Serum Albumin	g/dl
Blood glucose	mg/dl

Hematocrit	%	
Blood pH		
24 Hour Urine Output	Cc/day	
White blood cell count (WBC)	Cu/mm	
Alveolo-arterial pO ₂ gradient (A-aDO ₂)		
Blood urea nitrogen (BUN)	mg/dl	
Partial pressure carbon dioxide in arterial blood (PaCO ₂)	mmHg	
Partial pressure oxygen in arterial blood (PaO ₂)	mmHg	
Fraction of inspired oxygen in a gas (FIO ₂)		

Coronary Artery Bypass Graft (CABG) information (if applicable)		
Emergency surgery	Yes	No
Ejection fraction		
Diabetes (medication dependent)	Yes	No
CABG was redone	Yes	No
Number of grafts		
IMA used	Yes	No
MIDUR	Yes	No

Co-morbidities							
Acute Renal Failure		Yes		No			
Acquired immunodeficiency syndrome		Yes		No			
Cancer		Yes		No		Metastasis	
Chronic obstructive pulmonary disease		Yes		No			
Congestive heart failure		Yes		No			
Cirrhosis		Yes		No			
Colon cancer		Yes		No			
Coma		Yes		No			
		Glasgow coma scale:					
Unable to obtain Glasgow coma scale (<i>please note reason</i>):							
Hepatic failure		Yes		No			
Immuno- suppression		Yes		No			
Lung cancer		Yes		No			
Lymphoma		Yes		No			
Leukemia		Yes		No			
Multiple myeloma		Yes		No			
Multiple organ system failure with cancer		Yes		No			
Multiple organ system failure with sepsis		Yes		No			
Other co-morbidities:							

Palliative Performance Scale (Circle One)					
PPS Level	Ambulation	Activity & Evidence of Disease	Self-care	Intake	Conscious Level
100%	Full	Normal activity & work No evidence of disease	Full	Normal	Full
90%	Full	Normal activity & work Some evidence of disease	Full	Normal	Full
80%	Full	Normal activity with effort Some evidence of disease	Full	Normal or reduced	Full
70%	Reduced	Unable normal job or work Significant disease	Full	Normal or reduced	Full
60%	Reduced	Unable hobby/housework Significant disease	Occasional assistance necessary	Normal or reduced	Full or confusion
50%	Mainly sit/lie	Unable to do any work Extensive disease	Considerable assistance required	Normal or reduced	Full or confusion
40%	Mainly in bed	Unable to do most activity Extensive disease	Mainly assistance	Normal or reduced	Full or drowsy +/- confusion
30%	Totally bed bound	Unable to do any activity Extensive disease	Total care	Normal or reduced	Full or drowsy +/- confusion
20%	Totally bed bound	Unable to do any activity Extensive disease	Total care	Minimal to sips	Full or drowsy +/- confusion
10%	Totally bed bound	Unable to do any activity Extensive disease	Total care	Mouth care only	Drowsy or comma +/- confusion
0%	Death	-	-	-	-

Karnofsky Performance Scale (Circle One)	
100	Normal no complaints; no evidence of disease
90	Able to carry on normal activity; minor signs or symptoms of disease
80	Normal activity with efforts; some signs or symptoms of disease
70	Cares for self; unable to carry on normal activity or to do active work
60	Requires occasional assistance, but is able to care for most personal needs
50	Requires considerable assistance and frequent medical care
40	Disabled; requires special care and assistance
30	Severely disabled; hospital admission is indicated although death not imminent
20	Very sick; hospital admission necessary; active supportive treatment necessary
10	Moribund; fatal processes progressing rapidly
0	Dead

Activities of Daily Living (ADL) Index For each area of functioning listed below, check the description that applies. (The word "assistance" means supervision, direction, or personal assistance.)		
BATHING: Sponge bath, tub bath, or shower.		
☐ Receives no assistance (gets into and out of tub is the usual means of bathing)	☐ Receives assistance in bathing only one part of the body (such as the back of a leg).	☐ Receives assistance in bathing more than one part of the body (or not bathed).
DRESSING: Gets clothes from closets and drawers, including underclothes and outer garments and uses fasteners, including suspenders if worn.		
☐ Gets clothes and gets completely dressed without assistance.	☐ Gets clothes and gets dressed without assistance except for tying shoes.	☐ Receives assistance in getting clothes or in getting dressed, or stays partly or completely undressed.
TOILETING: Goes to the room termed "toilet" for bowel movement/urination, cleans self afterward and arrange clothes.		
☐ Goes to toilet room. Clean self, and arrange clothes without assistance. (May use object for support such as cane, or wheelchair and may manage night bedpan or commode, emptying it in morning.)	☐ Receives assistance in going to toilet room or in cleaning self or arranging clothes after elimination or in use of night bedpan or commode.	☐ Doesn't go to toilet room for the elimination process.
TRANSFER:		
☐ Moves into and out of bed as well as into and out of chair without assistance. (May use object such as cane or walker for support).	☐ Moves into or out of bed or chair without assistance.	☐ Doesn't get out of bed.
CONTINENCE:		
☐ Controls urination and bowel movement completely by self.	☐ Has occasional accidents.	☐ Supervision helps keep control of urination or bowel movement, or catheter is used, or is incontinent.
FEEDING:		
☐ Feeds self without assistance.	☐ Feeds self, except for assistance in cutting meat or buttering bread.	☐ Receives assistance in feeding or is fed partly or completely through tubes or by IV fluids.
INDEX A: Independent in all six functions. B: Independent in all but one of these functions. C: Independent in all but bathing and one additional function.		

D: Independent I all but bathing dressing and one additional function.

E: Independent in all but bathing, dressing, toileting, and one additional function.

F: Independent I all but bathing, dressing, toileting, transferring, and one additional function.

G: Dependant in all six functions.

Other: Dependant in at least two functions, but not classifiable as C, D, E, or F/

☐ **Indicates Independence**

☐ **Indicates Dependence**

ECOG Performance Status (ECOG-PS) (Circle One)

Grade	Description
0	Fully active, able to carry on all pre-disease performance without restriction
1	Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light sedentary nature, e.g., light house work, office
2	Ambulatory and capable of all self-care but unable to carry out any work activity. Up and about more than 50% of waking hours
3	Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
4	Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
5	Dead

Notes:

